The Prof G Pod with Scott Galloway
The Prof G Pod with Scott Galloway

Why People Are Losing Faith in Healthcare

June 4, 2026

AI Summary

5 min read

Why People Are Losing Faith in Healthcare

David Ricks, chair and CEO of Eli Lilly, joined Scott Galloway to discuss why his company became the first healthcare firm to reach a trillion-dollar valuation, the real promise and limits of GLP-1 drugs, and why Americans are increasingly turning to unregulated peptides as a symptom of a broken healthcare system.

Lilly was founded 150 years ago by a Civil War colonel who was a pharmacist. He saw soldiers dying from infections and terrible medical care, so he created a company that did something novel: list every ingredient on the bottle and sign each bottle himself. That signature remains the company's brand today. "The idea was quality and transparency," Ricks says. "His first hire was a scientist." Every product Lilly makes eventually goes off patent and revenue goes to zero, so the company has had to reinvent itself repeatedly. The current reinvention centers on GLP-1 therapies, which have made Lilly the first healthcare company to reach a trillion-dollar valuation.

Why GLP-1s Are Different from Other Drugs

Continue reading the full summary in the app — free to try.

Read Full Summary →

Free • No credit card required

Listen to Audio Summary Open in App

What you'll learn

  • 1 (03:36) **Eli Lilly's 150-Year Origin Story** - CEO Dave Ricks explains how a Civil War colonel founded the company on principles of quality and transparency, and why the company must constantly reinvent itself as patents expire.
  • 2 (05:14) **Why GLP-1s Are a "More Transformative Technology Than AI"** - Ricks agrees with Galloway's thesis, explaining the unique properties of these drugs: they work almost universally, and people actually like being on them.
  • 3 (07:15) **The Deficit, Healthcare Costs, and the Obesity Link** - Galloway argues that addressing the national deficit requires tackling healthcare costs, which requires tackling obesity.
  • 4 (09:21) **Beyond Weight Loss: Inflammation, Addiction, and Cancer** - Ricks outlines the expanding potential applications of GLP-1 technology.
  • 5 (14:52) **The Cost Problem and the "Subscription" Business Model** - Galloway presses on the tension between high list prices and the need to reach lower-income populations who would benefit most.
  • 6 (22:36) **Peptides Explained: The Real vs. The Hype** - Ricks clarifies what a peptide actually is and warns against the booming unregulated online peptide market.
  • 7 (26:02) **Why People Are Losing Faith in Healthcare** - Ricks connects the rise of unregulated peptide sales to a broader crisis of trust in the healthcare system.

+ Full timestamped outline available in the app

Guests on this episode

David Ricks Scott Galloway

Show Notes

David Ricks, Chair and CEO of Eli Lilly, joins Scott to discuss the rise of GLP-1 drugs, the future of obesity treatment, and why America's healthcare system is facing a crisis of trust. They explore healthcare costs, addiction, unregulated peptides, pharmaceutical innovation, and the role AI could play in the next generation of drug discovery.


Want to listen to this and other episodes ad-free? You can, if you subscribe at profgmedia.com.

Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Prof G Pod with Scott Galloway

More from this podcast

The Prof G Pod with Scott Galloway →